Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition
Drug Metabolism and Disposition · 2026-03 · 54 (3) · 100246
DOI: 10.1016/j.dmd.2026.100246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-03. Verfasst von Vishakha Tambe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Campus, Oklahoma City, Oklahoma. Hauptthemen laut MEDLINE: Protein Processing, Post-Translational, Solute Carrier Organic Anion Transporter Family Member 1B3, Lysine, Histone Deacetylase 6. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Organic anion transporting polypeptide (OATP) 1B3 plays a clinically significant role in hepatic drug disposition. Lysine acetylation, a key post-translational modification, has not been investigated for OATP1B3. This study determined the lysine acetylation status of OATP1B3 by proteomics and assessed the impact of inhibition of lysine deacetylase (KDAC) 6, a major cytosolic KDAC, on OATP1B3 acetylation and transport function. Proteomics revealed 7 acetylation sites, including 5 with additional ubiquitin-like modifications, and 4 phosphorylation sites (T10, S293, S295, S683). In human embryonic kidney 293 (HEK293)-Myc-FLAG-OATP1B3 cells, preincubation with the selective KDAC6 inhibitor tubacin (TBC) (5 μM, 24 hours), markedly reduced OATP1B3-mediated transport of [3H]cholecystokinin-8 (CCK-8), a specific substrate, and [3H]estradiol-17β-D-glucuronide to 0.15 ± 0.03-fold and 0.19 ± 0.01-fold of the control, respectively, without affecting OATP1B3 mRNA, protein levels, or membrane localization determined by real-time reverse transcription polymerase chain reaction, immunoblotting, and confocal microscopy. TBC treatment increased K664 acetylation to 2.12 ± 1.03-fold of the control (P < .05). Consistently, the acetylation-mimetic K664Q variant exhibited reduced transport compared with the acetylation-null K664R variant (P < .05). Treatment with a second KDAC6 selective inhibitor, WT-161 (3 μM, 5 hours), similarly reduced OATP1B3-mediated [3H]CCK-8 transport. In cultured primary human hepatocytes, TBC treatment for 4, 8, and 24 hours decreased [3H]CCK-8 transport to 0.34 ± 0.02-fold, 0.27 ± 0.03-fold, and 0.37 ± 0.03-fold of the control, respectively (all P < .05). The study reveals a novel post-translational modification of OATP1B3 by lysine acetylation and demonstrates impaired transporter function following KDAC6 inhibition, likely involving increased acetylation at K664, thereby providing new insight into OATP1B3-mediated drug-drug interactions driven by KDAC6 activity. SIGNIFICANCE STATEMENT: This study identifies lysine acetylation as a novel post-translational modification of organic anion transporting polypeptide (OATP)1B3 and demonstrates that altered lysine acetylation following inhibition of lysine deacetylase 6 reduces OATP1B3 transport function. These findings provide a mechanistic basis for altered hepatic drug disposition and highlight a new pathway through which drug-drug interactions involving OATP1B3 may occur.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Campus, Oklahoma City, Oklahoma.
- Department of Nutritional Sciences, College of Allied Health, University of Oklahoma Health Campus, Oklahoma City, Oklahoma.
- Proteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, North Carolina.
- Department of Biostatistics and Epidemiology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Campus, Oklahoma City, Oklahoma. Electronic address: wei-yue@ou.edu.
Förderung
- NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- University of Oklahoma Health Sciences Center
- National Institutes of Health Office of the Director
- Presbyterian Health Foundation
- National Institutes of Health National Cancer Institute
Zitieren
APA
Tambe, V., Niyonshuti, P., Aditya, V., Hays, F. A., Kayesh, R., Soderblom, E. J., Xu, C., & Yue, W. (2026). Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition. Drug Metabolism and Disposition, 54(3), 100246. https://doi.org/10.1016/j.dmd.2026.100246
Vancouver
Tambe V, Niyonshuti P, Aditya V, Hays FA, Kayesh R, Soderblom EJ, et al. Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition. Drug Metabolism and Disposition. 2026;54(3):100246. doi:10.1016/j.dmd.2026.100246
BibTeX
@article{Tambe2026,
author = {Tambe, Vishakha and Niyonshuti, Pascaline and Aditya, Vikram and Hays, Franklin A and Kayesh, Ruhul and Soderblom, Erik J and Xu, Chao and Yue, Wei},
title = {Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {3},
pages = {100246},
doi = {10.1016/j.dmd.2026.100246}
}
EUVIMED